AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Dividend history for AbbVie Inc. (ABBV)
AbbVie Inc. made a total of 49 dividend payments.
The sum of all dividends (adjusted for stock splits) is : $47.31
Dividend payments for AbbVie Inc. (ABBV) from 2013 to 2025
Annual dividend payments
| Date | Dividend | Adj Dividend |
|---|---|---|
| January 15, 25 | $1.64 | $1.64 |
| October 15, 24 | $1.55 | $1.55 |
| July 15, 24 | $1.55 | $1.55 |
| April 12, 24 | $1.55 | $1.55 |
| January 12, 24 | $1.55 | $1.55 |
| October 12, 23 | $1.48 | $1.48 |
| July 13, 23 | $1.48 | $1.48 |
| April 13, 23 | $1.48 | $1.48 |
| January 12, 23 | $1.48 | $1.48 |
| October 13, 22 | $1.41 | $1.41 |
| July 14, 22 | $1.41 | $1.41 |
| April 13, 22 | $1.41 | $1.41 |
| January 13, 22 | $1.41 | $1.41 |
| October 14, 21 | $1.30 | $1.30 |
| July 14, 21 | $1.30 | $1.30 |
| April 14, 21 | $1.30 | $1.30 |
| January 14, 21 | $1.30 | $1.30 |
| October 14, 20 | $1.18 | $1.18 |
| July 14, 20 | $1.18 | $1.18 |
| April 14, 20 | $1.18 | $1.18 |
| January 14, 20 | $1.18 | $1.18 |
| October 11, 19 | $1.07 | $1.07 |
| July 12, 19 | $1.07 | $1.07 |
| April 12, 19 | $1.07 | $1.07 |
| January 14, 19 | $1.07 | $1.07 |
| October 12, 18 | $0.96 | $0.96 |
| July 12, 18 | $0.96 | $0.96 |
| April 12, 18 | $0.96 | $0.96 |
| January 11, 18 | $0.71 | $0.71 |
| October 12, 17 | $0.64 | $0.64 |
| July 12, 17 | $0.64 | $0.64 |
| April 11, 17 | $0.64 | $0.64 |
| January 11, 17 | $0.64 | $0.64 |
| October 12, 16 | $0.57 | $0.57 |
| July 13, 16 | $0.57 | $0.57 |
| April 13, 16 | $0.57 | $0.57 |
| January 13, 16 | $0.57 | $0.57 |
| October 13, 15 | $0.51 | $0.51 |
| July 13, 15 | $0.51 | $0.51 |
| April 13, 15 | $0.51 | $0.51 |
| January 13, 15 | $0.49 | $0.49 |
| October 10, 14 | $0.42 | $0.42 |
| July 11, 14 | $0.42 | $0.42 |
| April 11, 14 | $0.42 | $0.42 |
| January 13, 14 | $0.40 | $0.40 |
| October 10, 13 | $0.40 | $0.40 |
| July 11, 13 | $0.40 | $0.40 |
| April 11, 13 | $0.40 | $0.40 |
| January 11, 13 | $0.40 | $0.40 |